Doctor’s Letter Triggers Pioglitazone Ban; India’s Health Ministry Under Fire
This article was originally published in PharmAsia News
Executive Summary
The waffling of India’s drug regulatory agency on the pioglitazone ban reveals cracks in the regulatory system.